Increased visibility to strengthen medicines supply chain preparedness
You can’t strengthen something if you don’t know where the weaknesses exist. USP Medicine Supply Map and insights that can lead to a stronger global medicines supply chain.
USP’s Medicine Supply Map - the first of its kind - enhances visibility into the upstream medicines supply chain to help identify vulnerabilities and deliver insights that can guide risk mitigation strategies and investment in supply chain resilience.
Increased visibility into the medicines supply chain through the Medicine Supply Map can help governments, manufacturers, distributors and providers identify and address vulnerabilities, lower quality risks, reduce the frequency and duration of potential drug shortages, and protect patients. Ultimately, it will help ensure patients have access to the medicines they need when they need it.
Targeting supply chain vulnerabilities
The vulnerabilities in the medicine supply chain exacerbated by the COVID-19 pandemic won’t go away without a concerted effort by manufacturers, government agencies and others. But stakeholders need to identify the vulnerabilities before they can fix them. Medicine Supply Map can help them do that.
Progress on preparedness
Increasing available information about the medicine supply chain reveals opportunities for preemptive measures that can make it stronger, supporting shortage prevention and mitigation efforts.
Early warning on potential disruptions
Medicine Supply Map analytics can alert stakeholders sooner that critical medicines are at increased risk for shortage, enabling them to take mitigative actions, such as diversifying suppliers or bolstering inventories, sooner to reduce the risk of shortages.
Click below to see latest Medicine Supply Map Insights.
